Difference between revisions of "Moxetumomab pasudotox (Lumoxiti)"
Jump to navigation
Jump to search
m |
m |
||
Line 19: | Line 19: | ||
[[Category:Immunotoxin]] | [[Category:Immunotoxin]] | ||
− | [[Category:Anti-CD22 | + | [[Category:Anti-CD22 immunotoxins]] |
[[Category:Hairy cell leukemia medications]] | [[Category:Hairy cell leukemia medications]] |
Latest revision as of 22:29, 3 July 2023
Mechanism of action
A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38)
Diseases for which it is used
History of changes in FDA indication
- 2018-09-13: Initial approval for adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA). (Based on Study 1053)
History of changes in EMA indication
- 2021-02-08: Initial authorization for treatment of adult patients with relapsed or refractory hairy cell leukaemia (HCL) after receiving at least two prior systemic therapies.
- 2021-07-23: Authorization withdrawn at manufacturer request, for commercial reasons
Also known as
- Generic name: moxetumomab pasudotox-tdfk
- Code names: CAT-8015, HA22
- Brand name: Lumoxiti